ARTICLE | Clinical News
ALD-301 regulatory update
August 17, 2009 7:00 AM UTC
Aldagen received an SPA from FDA for a double-blind, placebo-controlled Phase III trial to evaluate ALD-301 for 6 months to treat advanced critical limb ischemia (CLI) in patients with no revasculariz...